Table 2.
Drugs implicated in drug-induced SLE.
| High risk | Moderate risk | Low risk | Very low risk | |
|---|---|---|---|---|
| Antiarrhythmics | • Procainamide (15–20%) | • Quinidine (<1%) | • Disopyramide | |
| • Propafenone | ||||
| Antihypertensives | • Hydralazine (5–8%) | • Methyldopa | • Clonidine | |
| • Captopril | • Enalapril | |||
| • Acebutol | • Labetalol | |||
| • Minoxidil | ||||
| • Pindolol | ||||
| • Prazosin | ||||
| Antipsychotics | • Chlorpromazine | • Chlorprothixene | ||
| • Lithium carbonate | ||||
| • Phenelzine | ||||
| Antibiotics | • Isoniazid | • Nitrofurantoin | ||
| • Minocycline | • Cefepime | |||
| Anticonvulsants | • Carbamazepine | • Ethosuximide | ||
| • Phenytoin | ||||
| • Primidone | ||||
| • Trimethadione | ||||
| Antithyroidals | • Propylthiouracil | |||
| Anti-inflammatories | • D-penicillamine | • Phenylbutazone | ||
| • Sulfasalazine | • NSAIDs | |||
| Diuretics | • Chlorthalidone | |||
| • Hydrochlorothiazide | ||||
| Anticholesterolemics | • Atorvastatin Fluvastatin | |||
| • Lovastatin Pravastatin Simvastatin | ||||
| Proton pump inhibitors | • Lansoprazole | |||
| • Omeprazole | ||||
| • Pantoprazole | ||||
| Chemotherapeutic agents | • Taxanes | |||
| • Cyclofosfamide | ||||
| • Doxorubicin | ||||
| • Fluorouracil | ||||
| • Anastrozole | ||||
| • Bortezomib | ||||
| Antiaggregants | • Ticlopidine | |||
| Biologicals | • Etanercept | |||
| • Infliximab | ||||
| • Adalimumab | ||||
| • IL-2 | ||||
| • IFN-α | ||||
| • IFN-1b |